The power of AI for Novonesis isn't the algorithm itself, but its application to a massive, well-structured proprietary dataset. Their organized library of 100,000 strains allows AI to rapidly predict protein shapes and accelerate R&D in ways competitors cannot match.

A key competitive advantage for AI companies lies in capturing proprietary outcomes data by owning a customer's end-to-end workflow. This data, such as which legal cases are won or lost, is not publicly available. It creates a powerful feedback loop where the AI gets smarter at predicting valuable outcomes, a moat that general models cannot replicate.

Since LLMs are commodities, sustainable competitive advantage in AI comes from leveraging proprietary data and unique business processes that competitors cannot replicate. Companies must focus on building AI that understands their specific "secret sauce."

As AI models become commoditized, the ultimate defensibility comes from exclusive access to a unique dataset. A startup with a slightly inferior model but a comprehensive, proprietary dataset (e.g., all legal records) will beat a superior, general-purpose model for specialized tasks, creating a powerful long-term advantage.

The vague concept of a 'data network effect' is now a real defensibility strategy in AI. The key is having a *live*, constantly updating proprietary dataset (e.g., real-time health data). This allows a commodity model to deliver superior results compared to a state-of-the-art model without access to that live data.

The company not only identifies targets from its elite patient cohort but also isolates the corresponding T-cell receptors (TCRs). Because these TCRs have been circulating safely in patients for years, they offer a strong starting point for safety. They are also naturally "highly selected," providing significant initial affinity for their targets, which can accelerate development.

A new 'Tech Bio' model inverts traditional biotech by first building a novel, highly structured database designed for AI analysis. Only after this computational foundation is built do they use it to identify therapeutic targets, creating a data-first moat before any lab work begins.

The company has established a near-monopolistic position in its niche by creating a massive data moat. While the entire external field had reportedly tested only 19 combinations for cell age effects, NewLimit has already tested over 22,000. This scale transforms them from a participant into the creator and dominant player in their therapeutic area.

Instead of analyzing a broad patient population, Yellowstone focuses on a hyper-specific cohort: 15 out of 2,000 AML patients who were not only cured by stem cell transplants but also experienced no immune toxicity. This "elite responder" approach aims to identify therapeutic targets that are inherently both effective and safe, learning directly from ideal human outcomes.